Cargando…

Inhibition of glycolysis-driven immunosuppression with a nano-assembly enhances response to immune checkpoint blockade therapy in triple negative breast cancer

Immune-checkpoint inhibitors (ICI) are promising modalities for treating triple negative breast cancer (TNBC). However, hyperglycolysis, a hallmark of TNBC cells, may drive tumor-intrinsic PD-L1 glycosylation and boost regulatory T cell function to impair ICI efficacy. Herein, we report a tumor micr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ren, Xijiao, Cheng, Zhuo, He, Jinming, Yao, Xuemei, Liu, Yingqi, Cai, Kaiyong, Li, Menghuan, Hu, Yan, Luo, Zhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10622423/ https://www.ncbi.nlm.nih.gov/pubmed/37919262 http://dx.doi.org/10.1038/s41467-023-42883-2

Ejemplares similares

Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer
por: Camorani, Simona, et al.
Publicado: (2020)

Tumour mitochondrial DNA mutations drive aerobic glycolysis to enhance checkpoint blockade
por: Mahmood, Mahnoor, et al.
Publicado: (2023)

ESMO20 YO for YO: highlights on immune checkpoint blockade for triple-negative breast cancer
por: Punie, K., et al.
Publicado: (2020)

Immune Checkpoint Blockades in Triple-Negative Breast Cancer: Current State and Molecular Mechanisms of Resistance
por: Kim, Hyungjoo, et al.
Publicado: (2022)

Neuronal CaMKK2 promotes immunosuppression and checkpoint blockade resistance in glioblastoma
por: Tomaszewski, William H., et al.
Publicado: (2022)

Targeting CXCL16 and STAT1 augments immune checkpoint blockade therapy in triple-negative breast cancer
por: Palakurthi, Bhavana, et al.
Publicado: (2023)

Immune checkpoint blockade impairs immunosuppressive mechanisms of regulatory T cells in B-cell lymphoma
por: Bauer, Vera, et al.
Publicado: (2021)

Immune checkpoint blockade in triple negative breast cancer influenced by B cells through myeloid-derived suppressor cells
por: Vito, Alyssa, et al.
Publicado: (2021)

Neoadjuvant Chemotherapy Improves the Immunosuppressive Microenvironment of Bladder Cancer and Increases the Sensitivity to Immune Checkpoint Blockade
por: Luo, Hao, et al.
Publicado: (2022)

Neoadjuvant Immune-Checkpoint Blockade in Triple-Negative Breast Cancer: Current Evidence and Literature-Based Meta-Analysis of Randomized Trials
por: Marinelli, Daniele, et al.
Publicado: (2020)

The therapeutic implications of immunosuppressive tumor aerobic glycolysis
por: Reinfeld, Bradley I., et al.
Publicado: (2021)

Designing supramolecular self-assembly nanomaterials as stimuli-responsive drug delivery platforms for cancer therapy
por: Liu, Yingqi, et al.
Publicado: (2023)

ZDHHC9: a promising therapeutic target for triple-negative breast cancer through immune modulation and immune checkpoint blockade resistance
por: Xu, Chao, et al.
Publicado: (2023)

The multikinase inhibitor Sorafenib enhances glycolysis and synergizes with glycolysis blockade for cancer cell killing
por: Tesori, Valentina, et al.
Publicado: (2015)

A New VISTA on combination therapy for negative checkpoint regulator blockade
por: Deng, Jie, et al.
Publicado: (2016)

Facts and Perspectives: Implications of tumor glycolysis on immunotherapy response in triple negative breast cancer
por: Schreier, Ashley, et al.
Publicado: (2023)

A protein-based cGAS-STING nanoagonist enhances T cell-mediated anti-tumor immune responses
por: Wang, Xuan, et al.
Publicado: (2022)

Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors
por: Crosby, Erika J., et al.
Publicado: (2018)

Loss of RBMS1 promotes anti-tumor immunity through enabling PD-L1 checkpoint blockade in triple-negative breast cancer
por: Zhang, Jinrui, et al.
Publicado: (2022)

Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade
por: Bommareddy, Praveen K., et al.
Publicado: (2019)

Checkpoint inhibitor therapy for metastatic triple-negative breast cancer
por: Heeke, Arielle L., et al.
Publicado: (2021)

Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors
por: Abdou, Yara, et al.
Publicado: (2022)

Identification of a novel glycolysis-related prognosis risk signature in triple-negative breast cancer
por: Ruan, Yuxia, et al.
Publicado: (2023)

A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and In Situ Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer
por: Sun, Kai, et al.
Publicado: (2022)

ADAM12 abrogation alters immune cell infiltration and improves response to checkpoint blockade therapy in the T11 murine model of triple-negative breast cancer
por: Wang, Guanpeng, et al.
Publicado: (2022)

Multifunctional Nanoplatform-Mediated Chemo-Photothermal Therapy Combines Immunogenic Cell Death with Checkpoint Blockade to Combat Triple-Negative Breast Cancer and Distant Metastasis
por: Zhu, Hui, et al.
Publicado: (2023)

C5aR1 blockade reshapes immunosuppressive tumor microenvironment and synergizes with immune checkpoint blockade therapy in high-grade serous ovarian cancer
por: Zhang, Chen, et al.
Publicado: (2023)

Corticosteroids and immune checkpoint blockade
por: Min, Le, et al.
Publicado: (2015)

Immune checkpoint blockade in HIV
por: Gubser, Celine, et al.
Publicado: (2022)

Biomimetic nanoprobe-augmented triple therapy with photothermal, sonodynamic and checkpoint blockade inhibits tumor growth and metastasis
por: Lin, Xiaohong, et al.
Publicado: (2022)

RNA Hydrogel Combined with MnO(2) Nanoparticles as a Nano-Vaccine to Treat Triple Negative Breast Cancer
por: Wang, Weicai, et al.
Publicado: (2021)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019)

Anlotinib Inhibits PFKFB3-Driven Glycolysis in Myofibroblasts to Reverse Pulmonary Fibrosis
por: Chen, Weimou, et al.
Publicado: (2021)

YTHDF1 upregulation mediates hypoxia-dependent breast cancer growth and metastasis through regulating PKM2 to affect glycolysis
por: Yao, Xuemei, et al.
Publicado: (2022)

Dual antibody-aided mesoporous nanoreactor for H(2)O(2) self-supplying chemodynamic therapy and checkpoint blockade immunotherapy in triple-negative breast cancer
por: Chen, Ying-Tzu, et al.
Publicado: (2023)

Immune checkpoints: A therapeutic target in triple negative breast cancer
por: Chawla, Akhil, et al.
Publicado: (2014)

Clinical outcomes of immune checkpoint blockades and the underlying immune escape mechanisms in squamous and adenocarcinoma NSCLC
por: Tian, Yaru, et al.
Publicado: (2020)

MCT4 blockade increases the efficacy of immune checkpoint blockade
por: Babl, Nathalie, et al.
Publicado: (2023)

LINC01605 promotes aerobic glycolysis through lactate dehydrogenase A in triple‐negative breast cancer
por: Wang, Wei, et al.
Publicado: (2022)

Manipulation of the crosstalk between tumor angiogenesis and immunosuppression in the tumor microenvironment: Insight into the combination therapy of anti-angiogenesis and immune checkpoint blockade
por: Zheng, Weiwei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p2375o0b61brm6eq3m60339ap1